{"id":"NCT02187471","sponsor":"Daiichi Sankyo","briefTitle":"Treatment of Pain Associated With Fibromyalgia","officialTitle":"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-16","primaryCompletion":"2017-01-06","completion":"2017-01-12","firstPosted":"2014-07-11","resultsPosted":"2020-11-09","lastUpdate":"2020-11-09"},"enrollment":1301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain Associated With Fibromyalgia"],"interventions":[{"type":"DRUG","name":"DS-5565","otherNames":["Mirogabalin"]},{"type":"DRUG","name":"Pregabalin","otherNames":["Other treatment - not comparator"]},{"type":"DRUG","name":"Placebo tablet","otherNames":["Tablet Control"]},{"type":"DRUG","name":"Placebo capsule","otherNames":["Capsule Control"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pregabalin","type":"OTHER"},{"label":"DS-5565 15 mg QD","type":"EXPERIMENTAL"},{"label":"DS-5565 15 mg BID","type":"EXPERIMENTAL"}],"summary":"The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.\n\nWeekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.","primaryOutcome":{"measure":"Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo","timeFrame":"Baseline up to Week 13 postdose","effectByArm":[{"arm":"Placebo","deltaMin":-1.9,"sd":0.135},{"arm":"Pregabalin 150 mg BID","deltaMin":-2.64,"sd":0.137},{"arm":"DS-5565 15 mg QD","deltaMin":-2.04,"sd":0.138},{"arm":"DS-5565 15 mg BID","deltaMin":-2.3,"sd":0.136}],"pValues":[{"comp":"OG000 vs OG002","p":"0.4601"},{"comp":"OG000 vs OG003","p":"0.0350"},{"comp":"OG000 vs OG001","p":"0.0001"},{"comp":"OG001 vs OG002","p":"0.0019"},{"comp":"OG001 vs OG003","p":"0.0761"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":154,"countries":["United States","Argentina","Austria","Belarus","Belgium","Chile","Colombia","Israel","Mexico","Poland","Portugal","Slovenia","Spain","Switzerland"]},"refs":{"pmids":["31284771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":324},"commonTop":["Headache","Dizziness","Weight increased","Somnolence","Nausea"]}}